vs

Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $74.7M, roughly 1.8× Health Catalyst, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs -121.9%, a 204.4% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs -6.2%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs -0.0%).

Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CTRE vs HCAT — Head-to-Head

Bigger by revenue
CTRE
CTRE
1.8× larger
CTRE
$134.9M
$74.7M
HCAT
Growing faster (revenue YoY)
CTRE
CTRE
+61.3% gap
CTRE
55.1%
-6.2%
HCAT
Higher net margin
CTRE
CTRE
204.4% more per $
CTRE
82.5%
-121.9%
HCAT
Faster 2-yr revenue CAGR
CTRE
CTRE
Annualised
CTRE
46.2%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTRE
CTRE
HCAT
HCAT
Revenue
$134.9M
$74.7M
Net Profit
$111.3M
$-91.0M
Gross Margin
Operating Margin
-115.3%
Net Margin
82.5%
-121.9%
Revenue YoY
55.1%
-6.2%
Net Profit YoY
113.5%
-340.3%
EPS (diluted)
$0.52
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRE
CTRE
HCAT
HCAT
Q4 25
$134.9M
$74.7M
Q3 25
$132.4M
$76.3M
Q2 25
$112.5M
$80.7M
Q1 25
$96.6M
$79.4M
Q4 24
$86.9M
$79.6M
Q3 24
$77.4M
$76.4M
Q2 24
$68.9M
$75.9M
Q1 24
$63.1M
$74.7M
Net Profit
CTRE
CTRE
HCAT
HCAT
Q4 25
$111.3M
$-91.0M
Q3 25
$74.9M
$-22.2M
Q2 25
$68.5M
$-41.0M
Q1 25
$65.8M
$-23.7M
Q4 24
$52.1M
$-20.7M
Q3 24
$33.4M
$-14.7M
Q2 24
$10.8M
$-13.5M
Q1 24
$28.7M
$-20.6M
Gross Margin
CTRE
CTRE
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
CTRE
CTRE
HCAT
HCAT
Q4 25
-115.3%
Q3 25
58.1%
-22.9%
Q2 25
61.3%
-46.0%
Q1 25
-25.4%
Q4 24
-22.0%
Q3 24
43.0%
-17.9%
Q2 24
15.1%
-20.8%
Q1 24
-30.5%
Net Margin
CTRE
CTRE
HCAT
HCAT
Q4 25
82.5%
-121.9%
Q3 25
56.6%
-29.1%
Q2 25
60.9%
-50.8%
Q1 25
68.1%
-29.9%
Q4 24
60.0%
-26.0%
Q3 24
43.2%
-19.3%
Q2 24
15.6%
-17.8%
Q1 24
45.6%
-27.6%
EPS (diluted)
CTRE
CTRE
HCAT
HCAT
Q4 25
$0.52
$-1.29
Q3 25
$0.35
$-0.32
Q2 25
$0.35
$-0.59
Q1 25
$0.35
$-0.35
Q4 24
$0.30
$-0.33
Q3 24
$0.21
$-0.24
Q2 24
$0.07
$-0.23
Q1 24
$0.22
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRE
CTRE
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$198.0M
$95.7M
Total DebtLower is stronger
$894.2M
$153.3M
Stockholders' EquityBook value
$4.0B
$245.8M
Total Assets
$5.1B
$502.6M
Debt / EquityLower = less leverage
0.22×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRE
CTRE
HCAT
HCAT
Q4 25
$198.0M
$95.7M
Q3 25
$712.5M
$91.5M
Q2 25
$306.1M
$97.3M
Q1 25
$26.5M
$342.0M
Q4 24
$213.8M
$392.0M
Q3 24
$377.1M
$387.3M
Q2 24
$495.1M
$308.3M
Q1 24
$451.2M
$327.8M
Total Debt
CTRE
CTRE
HCAT
HCAT
Q4 25
$894.2M
$153.3M
Q3 25
$893.8M
$153.1M
Q2 25
$1.2B
$153.0M
Q1 25
$822.1M
$382.9M
Q4 24
$396.9M
$382.4M
Q3 24
$396.7M
$345.0M
Q2 24
$671.1M
Q1 24
$595.9M
Stockholders' Equity
CTRE
CTRE
HCAT
HCAT
Q4 25
$4.0B
$245.8M
Q3 25
$4.0B
$331.9M
Q2 25
$3.3B
$347.5M
Q1 25
$2.9B
$376.8M
Q4 24
$2.9B
$365.2M
Q3 24
$2.4B
$355.0M
Q2 24
$1.9B
$357.0M
Q1 24
$1.7B
$357.2M
Total Assets
CTRE
CTRE
HCAT
HCAT
Q4 25
$5.1B
$502.6M
Q3 25
$5.1B
$587.1M
Q2 25
$4.7B
$616.2M
Q1 25
$3.9B
$891.5M
Q4 24
$3.4B
$858.9M
Q3 24
$2.9B
$813.0M
Q2 24
$2.7B
$691.7M
Q1 24
$2.3B
$695.1M
Debt / Equity
CTRE
CTRE
HCAT
HCAT
Q4 25
0.22×
0.62×
Q3 25
0.22×
0.46×
Q2 25
0.35×
0.44×
Q1 25
0.28×
1.02×
Q4 24
0.14×
1.05×
Q3 24
0.16×
0.97×
Q2 24
0.35×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRE
CTRE
HCAT
HCAT
Operating Cash FlowLast quarter
$394.0M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRE
CTRE
HCAT
HCAT
Q4 25
$394.0M
$9.9M
Q3 25
$100.9M
$-464.0K
Q2 25
$100.8M
$-9.0M
Q1 25
$71.4M
$280.0K
Q4 24
$244.3M
$-3.5M
Q3 24
$67.2M
$6.2M
Q2 24
$53.0M
$1.6M
Q1 24
$48.8M
$10.3M
Free Cash Flow
CTRE
CTRE
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
CTRE
CTRE
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
CTRE
CTRE
HCAT
HCAT
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
CTRE
CTRE
HCAT
HCAT
Q4 25
3.54×
Q3 25
1.35×
Q2 25
1.47×
Q1 25
1.08×
Q4 24
4.68×
Q3 24
2.01×
Q2 24
4.92×
Q1 24
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTRE
CTRE

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons